Daniel H. Shevrin

Evanston Hospital

Claim

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 97 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Supplemental Figure 2 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (Brcaaway)

Maha Hussain,Masha Kocherginsky,Neeraj Agarwal,Nabil Adra,Jingsong Zhang,Channing J. Paller,Joel Picus,Zachery R. Reichert,Russell Z. Szmulewitz,Scott T. Tagawa,Timothy M. Kuzel,Latifa A. Bazzi,Stephanie Daignault-Newton,Young E. Whang,Robert Dreicer,Ryan D. Stephenson,Matthew B. Rettig,Daniel Shevrin,Travis Gerke,Arul M. Chinnaiyan,Emmanuel S. Antonarakis

crossref（2024）

Cited0Views0Bibtex

BRCAAway: A Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mcrpc) Bearing Homologous Recombination-Repair Mutations (Hrrm)

Maha H. A. Hussain,Masha Kocherginsky,Neeraj Agarwal,Nabil Adra,Jingsong Zhang,Channing Judith Paller,Joel Picus,Zachery R. Reichert,Russell Zelig Szmulewitz,Scott T. Tagawa,Timothy Kuzel,Latifa Bazzi,Stephanie Daignault-Newton,Young E. Whang,Robert Dreicer,Ryan D. Stephenson,Matthew Rettig,Daniel Shevrin,Arul Chinnaiyan,Emmanuel S. Antonarakis

JOURNAL OF CLINICAL ONCOLOGYno. 4_SUPPL (2024): 19-19

Cited8Views0Bibtex

Supplemental Table 4 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (Brcaaway)

crossref（2024）

Cited0Views0Bibtex

Supplemental Table 2 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (Brcaaway)

crossref（2024）

Cited0Views0Bibtex

PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients with High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)

Rahul Aggarwal,Glenn Heller,David W. Hillman,Han Xiao,Joel Picus,Mary-Ellen Taplin,Tanya Dorff,Leonard Appleman,Douglas Weckstein,Akash Patnaik,Alan Bryce,Daniel Shevrin,James Mohler,Daniel Anderson,Arpit Rao,Scott Tagawa,Alan Tan,Susan Halabi,Katharine Dooley, Patrick O'Brien,Ronald Chen,Charles J. Ryan,Scott E. Eggener,Michael J. Morris

Journal of Clinical Oncology（2024）

Cited5Views0WOSBibtex

Ronald C. Chen,Gina L. Mazza,Briant Fruth,Han Xiao,Joel Picus,Mary Ellen Taplin,Tanya B. Dorff,Leonard Joseph Appleman,Douglas Jay Weckstein,Akash Patnaik,Alan Haruo Bryce,Daniel Shevrin,James L. Mohler,Daniel M. Anderson,Arpit Rao,Alan Tan,Charles J. Ryan,Scott Eggener,Michael J. Morris,Rahul Raj Aggarwal

Journal of Clinical Oncologyno. 16_suppl (2024): 5006-5006

Cited0Views0Bibtex

Supplemental Figure 1 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (Brcaaway)

crossref（2024）

Cited0Views0Bibtex

Supplemental Table 1 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (Brcaaway)

crossref（2024）

Cited0Views0Bibtex

Supplemental Table 6 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (Brcaaway)

crossref（2024）

Cited0Views0Bibtex

Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (Brcaaway)

Clinical Cancer Research (2024)

Cited1Views0WOSBibtex

Author Statistics

#Papers: 97

#Citation: 6441

H-Index: 26

G-Index: 69

Sociability: 7

Diversity: 3

Activity: 46

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn